IPM Take
Blood-based screening could help close a major adherence gap in colorectal cancer. But a test is not a programme. If positive results do not lead to colonoscopy, navigation and treatment, the technology becomes a warning signal without a pathway.
Executive Summary
Freenome reported top-line validation results for an updated SimpleScreen CRC blood-based colorectal screening test. The company said the study met primary and secondary endpoints, with 80.4% sensitivity for colorectal cancer, 18.2% sensitivity for advanced precancerous lesions, 41.9% sensitivity for advanced precancerous lesions with high-grade dysplasia, and 90% specificity for no findings on colonoscopy. The PREEMPT CRC study enrolled 48,995 asymptomatic average-risk adults aged 45 to 85 at more than 200 sites. Freenome submitted a PMA for the first-generation SimpleScreen CRC test in August 2025 and intends to submit a supplemental PMA for the next-generation version.
Why it matters
- Patients / advocates: A blood test may reduce friction for people who avoid stool tests or colonoscopy, but a positive result still needs follow-up.
- Public authorities: Screening policy must measure completed diagnostic pathways, not only test uptake.
- Diagnostics / pathology: Advanced precancerous lesion detection is the prevention battleground, not just cancer detection.
- Payers: Coverage decisions will need to weigh convenience, sensitivity, specificity, adherence and downstream colonoscopy capacity.
The attraction is obvious: a blood draw is easier to sell than a colonoscopy.
That is why blood-based colorectal cancer screening has become one of the hottest fights in early detection. Freenome’s updated SimpleScreen CRC test now reports 80.4% sensitivity for colorectal cancer and 90% specificity for no findings on colonoscopy. More importantly for prevention, the updated test reported 18.2% sensitivity for advanced precancerous lesions and 41.9% sensitivity for those with high-grade dysplasia.
That improvement matters. Detecting cancer is important. Preventing cancer is better.
But this story needs discipline. A blood test does not magically fix screening. It may improve adherence among people who are not up to date, and Freenome notes that more than 50 million eligible U.S. adults remain behind on recommended colorectal screening. But the public-health benefit depends on what happens after the blood draw.
A positive screening result must trigger colonoscopy. Colonoscopy must be available. Patients must be navigated. Costs must be covered. Rural and underserved communities must not be left with a test result and no realistic pathway to diagnostic confirmation.
This is where screening technologies are often oversold. Companies market convenience. Health systems have to deliver completion.
The data also need to mature in the right way. These are top-line results from a company announcement, not yet a fully peer-reviewed implementation record. The test still sits within an FDA review and future supplemental submission pathway. That does not weaken the importance of the signal, but it should keep the policy conversation grounded.
The future of colorectal screening may well include blood. But blood only becomes prevention when the system behind it does its job.
